Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)

NCT05247203 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT05247203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05247203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2022
Completion date
November 13, 2023
Enrollment
92 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus